GLP1R and nephrolithiasis: Compared to patients treated with antidiabetic drugs (excluding GLP-1 receptor agonists), patients treated only with GLP-1 receptor agonists have been observed to be at increased risk of certain comorbidities, such as (1) cardiovascular disorders (hypotension, syncope), (2) gastrointestinal disorders and pancreatitis, (3) degenerative joint diseases, and (4) nephrolithiasis and interstitial nephritis.